Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations i...

Full description

Saved in:
Bibliographic Details
Published in:J Adv Pract Oncol
Main Authors: Myers, Rebecca A., Wirth, Scott, Williams, Sherry, Kiel, Patrick J.
Format: Artigo
Language:Inglês
Published: Harborside Press 2018
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6347084/
https://ncbi.nlm.nih.gov/pubmed/30719396
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items